[ad_1]
G42 Healthcare is a leading Abu Dhabi-based medtech company transforming the UAE’s healthcare landscape through artificial intelligence and advanced medical technology, and has stepped up its efforts to provide clinical genetic testing solutions in the UAE. The company has launched more than 250 comprehensive clinical genetic testing kits using state-of-the-art sequencing technology with the shortest turnaround time.
In his comments, Dr. Fahed Al Marzooqi, Chief Operating Officer, G42 Healthcaresaid: “As part of our work to support the health of future generations and provide better healthcare every day, Biogenix Labs is expanding its clinical genetics offerings in the region and strengthening its reputation as the regional testing provider of choice.”
“We will soon expand this service to the Kingdom of Saudi Arabia and the wider GCC region,” Dr. Al Marzooqi Summarize.
These diagnostic tests, or biomarkers, help assess high-risk patients and aid in early detection of disease, prognosis, treatment options, treatment response, and chance of recurrence. With the enhanced service offering more than 5,000 whole genome sequencing per week and more than 50,000 whole exome sequencing per week, it opens up the possibility of preventive and precision treatment that will change the healthcare landscape in the UAE, making it Ability to transition from illness care to healthcare.
Biogenix Labs’ current portfolio of clinical tests includes cancer screening, rare and metabolic diseases, genetic status of newborns, and carrier screening tests to determine a couple’s risk of passing a genetic disorder to offspring and non-invasive prenatal test.
Clinical genetic solutions will be delivered through Biogenix Labs, part of G42 Healthcare, as part of the company’s mission to provide insight and advance the early diagnosis and treatment of cancer, rare and metabolic diseases, and other genetic diseases in the region.
Soon, clinical genetics products will be followed by consumer genomics test equivalents, which will pave the way for personalized health plans in the UAE and beyond.
About G42 Healthcare
G42 Healthcare is a leading healthtech company with a mission to develop world-class healthcare in the UAE and beyond by leveraging data and advanced medical technologies to unlock the potential of personalised and preventive care and transform traditional healthcare ecosystems Healthcare industry. We established Biogenix Labs, the UAE’s first COVID-19 accredited large-scale throughput laboratory, and facilitated the 4Humanity clinical trial, the world’s first three-in-a-lifetime inactivated vaccine against COVID-19 Phase 3 trial, more than 43,000 volunteers from more than 125 countries in the pan-Arab region, established the region’s first dedicated contract research organization (IROS) for clinical research with and for local populations , supporting the UAE’s healthcare authorities in implementing national vaccinations, conducting research into new vaccines and pharmacotherapies, and establishing the Omics Centre of Excellence, the largest and most technologically advanced omics facility in the region, and is the backbone of the UAE Genome Initiative, which is a The world’s most comprehensive population genomics program. For more information on G42 Healthcare, please visit https://www.g42healthcare.ai
[ad_2]
Source link